GlassScriptPhysician profile
Melissa Beth Pongratz
NPI 1508486762
$9,705.40
in general payments reported to CMS, 2019-2025
27 companies · $2,187 in 2025
The $2,187 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $62.26 · 2021: $798 · 2022: $1,607 · 2023: $1,525 · 2024: $3,525 · 2025: $2,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,238.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,004.94 | 2022-2025 | Clareon Panoptix Pro, Hydrus Microstent, Voyager Dslt |
| Biotissue Holdings INC. | $1,315.08 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $1,283.43 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Tarsus Pharmaceuticals, INC. | $544.58 | 2024-2025 | Xdemvy |
| Abbvie INC. | $509.22 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $460.10 | 2020-2025 | |
| Glaukos Corporation | $402.24 | 2021-2025 | Idosetr |
| Oyster Point Pharma, INC. | $376.27 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Dompe US, INC. | $332.99 | 2024-2025 | Oxervate |
| Amgen INC. | $290.43 | 2024-2025 | Tepezza |
| Lumenis Be INC | $271.48 | 2023 | Optilight |
| Apellis Pharmaceuticals, INC. | $256.74 | 2023-2024 | Syfovre |
| Rxsight INC | $248.91 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Nova Eye, INC. | $231.96 | 2024 | |
| Lkc Technologies, INC. | $181.94 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $171.57 | 2021 | |
| Horizon Therapeutics Plc | $169.27 | 2022-2023 | Tepezza |
| Allergan, INC. | $143.10 | 2021 | |
| Sight Sciences, INC. | $120.07 | 2022-2023 | Omni Surgical System |
| Genmab U.S., INC. | $105.27 | 2024 | Tivdak |
| Harrow Eye, LLC | $105.03 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $43.80 | 2022-2023 | |
| Thea Pharma INC. | $43.54 | 2025 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $31.05 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $29.60 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.01 | 2021 | |
| Alimera Sciences, INC. | $15.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Pongratz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.